Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 4/20 | 0.50 |
| ▸ | MALT1 | Q9UDY8 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | GHSR | Q92847 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2011928 | 0.86 | MLNR (0.53) | MLNRMALT1TRPV1CYP3A4CYP2D6 | |
| SCHEMBL2009209 | 0.81 | KDM4E (0.48) | MLNRMALT1ALDH1A1MAPT | |
| SCHEMBL2011340 | 0.77 | MLNR (0.53) | MLNRALDH1A1DRD2DRD3TRPV1 | |
| SCHEMBL2009322 | 0.77 | MLNR (0.50) | MLNRMALT1 | |
| SCHEMBL2008145 | 0.74 | MLNR (0.50) | MLNRMALT1ALDH1A1DRD2DRD3 | |
| SCHEMBL1728915 | 0.74 | KMT2A (0.50) | MALT1ALDH1A1TRPV1CYP3A4 | |
| SCHEMBL2008677 | 0.73 | MALT1 (0.46) | MALT1TRPV1MAPK1 | |
| SCHEMBL4732425 | 0.72 | FPR2 (0.49) | ALDH1A1DRD2DRD3MAPTMAPK1 | |
| SCHEMBL4733366 | 0.72 | MALT1 (0.46) | MALT1ALDH1A1DRD2DRD3 | |
| SCHEMBL2008564 | 0.71 | MLNR (0.51) | MLNRMALT1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964602-B2 | Biaryl compounds useful as agonists of the Gpr38 receptor | GLAXO GROUP LIMITED (GB) | 2011-06-21 | — | — | US | disclosed |
| EP-1960390-B1 | BIARYL COMPOUNDS USEFUL AS AGONISTS OF THE GPR38 RECEPTOR | GLAXO GROUP LTD (GB) | 2010-07-21 | — | — | EP | disclosed |
| US-20080306083-A1 | Biaryl Compounds Useful as Agonists of the Gpr38 Receptor | GLAXO GROUP LIMITED | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306083-A1 | Biaryl Compounds Useful as Agonists of the Gpr38 Receptor | GPR88, GPR68, GPBAR1 | MLNR 47/4885MALT1 1182/4885ALDH1A1 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.